Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

TG Therapeutics, Ligand ink licensing deal to develop inhibitors of IRAK4 US-based clinical-stage biopharmaceutical firm TG Therapeutics has entered into an agreement with Ligand Pharmaceuticals (LGND) to license exclusive global rights to develop and commercialize Ligand's Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitor research program. Drug Research > Drug Discovery & Development > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Regeneron, Bayer release positive Phase III trial results of EYLEA to treat DME
By PBR Staff Writer
Regeneron Pharmaceuticals and Bayer HealthCare have released positive results from the Phase III VIVID-DME trial of EYLEA (aflibercept) Injection indicated to treat diabetic macular edema (DME).
Drug Research > Drug Delivery > News
Durata Therapeutics launches DALVANCE for injection in US
By PBR Staff Writer
Durata Therapeutics has launched DALVANCE (dalbavancin) for injection in the US to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI).
Drug Research > Drug Delivery > News

Drug Discovery & Development

Cynapsus Therapeutics commences Phase II clinical trials in US
Cynapsus Therapeutics, a specialty pharmaceutical company focused on Parkinson's disease, has announced that following communication from the United States Food and Drug Administration, Phase II clinical studies for APL-130277 will commence immediately.
Drug Research > Drug Discovery & Development > News
MYOS enters into R&D agreement with Cloud Pharmaceuticals
MYOS, an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, has entered into a research and development agreement with Cloud Pharmaceuticals.
Drug Research > Drug Discovery & Development > News